rs193922339 — GCK

GCK p.Phe316Tyr — A Raised Glucose Thermostat, Not Diabetes as Usual

Every pancreatic beta cell contains a molecular glucose sensor — the enzyme glucokinase¹¹ glucokinase
GCK (hexokinase-4): the first enzyme to phosphorylate glucose in beta cells, setting the threshold at which insulin secretion begins. Normal GCK triggers insulin release when blood glucose rises above ~5 mmol/L. This variant, GCK p.Phe316Tyr (rs193922339), substitutes phenylalanine with tyrosine at position 316 in the large catalytic subdomain of the protein. The result is reduced glucokinase activity — and a glucose "thermostat" that is chronically set several points too high, producing lifelong mild fasting hyperglycemia that is almost always asymptomatic.

This is MODY2²² MODY2
Maturity-Onset Diabetes of the Young type 2, also called GCK-MODY: the most common form of monogenic diabetes, caused by heterozygous loss-of-function variants in the GCK gene. Unlike type 1 or type 2 diabetes, MODY2 is stable, non-progressive, and rarely requires medication, not the slowly progressive metabolic failure of type 2 diabetes.

The Mechanism

Glucokinase is the rate-limiting glucose sensor in pancreatic beta cells. Wild-type GCK has a sigmoidal glucose–response curve with a half-saturation glucose concentration (S0.5) near 8 mM — it effectively becomes active only when postprandial glucose rises into that range, triggering the insulin surge that keeps blood sugar in the normal range. In heterozygous GCK-MODY carriers, only one functional copy of GCK is present. The mutant p.Phe316Tyr protein resides in the large subdomain at a structural helix-turn element (residues 316-318) that contributes to the enzyme's conformational dynamics. With 50% of normal GCK activity, the beta cell's effective glucose threshold shifts upward by approximately 1.5–2.5 mmol/L. The body reaches a new, stable setpoint — fasting glucose typically ranging 5.4–8.0 mmol/L³³ fasting glucose typically ranging 5.4–8.0 mmol/L
97–144 mg/dL in most carriers, with HbA1c 5.6–7.6% — and holds there for life.

The Evidence

Carmody et al. 2016⁴⁴ Carmody et al. 2016
GCK-MODY in the US National Monogenic Diabetes Registry: Frequently Misdiagnosed and Unnecessarily Treated. Acta Diabetol, 2016 analysed 120 GCK-MODY patients: median pre-diagnosis HbA1c was 6.4%, and almost half (49%) had been given glucose-lowering medications unnecessarily. After genetic confirmation, 79.2% safely discontinued treatment with no change in glycaemic control — confirming the condition's pharmacological non-responsiveness.

Kleinberger & Pollin 2015⁵⁵ Kleinberger & Pollin 2015
Undiagnosed MODY: Time for Action. Curr Diab Rep estimated that ~95% of MODY cases in the USA remain undiagnosed, with most GCK-MODY patients incorrectly labelled as type 2 or type 1 diabetic. GCK-MODY carriers do not develop the typical complications of diabetes because hyperglycemia does not worsen beyond the new setpoint.

Galán et al. 2005⁶⁶ Galán et al. 2005
Biochem J functionally characterised multiple novel GCK MODY missense variants, finding that all patients presented with mild fasting hyperglycemia (6.6–8.0 mM), responded well to dietary management, and showed no progression to diabetic complications over follow-up — consistent with the broadly benign prognosis of single-copy GCK loss.

In pregnancy, Timsit et al. 2022⁷⁷ Timsit et al. 2022
Front Endocrinol showed that maternal GCK-MODY affects fetal growth differently depending on whether the fetus inherited the variant. Non-carrying fetuses face 33–65% macrosomia rates compared with only 4–13% in fetuses that inherited the mutation. Crucially, the fetal genotype — not maternal insulin treatment — was the primary driver of macrosomia risk.

Practical Actions

The key insight from genetic diagnosis is what to stop rather than start. If previously labelled as type 2 diabetic and started on metformin or other agents, most GCK-MODY patients can safely discontinue medication under physician supervision without any worsening of glycaemia. Fasting glucose levels need to be monitored but not aggressively treated.

Dietary management focuses on reducing postprandial glucose spikes rather than aiming for normoglycaemia — pushing glucose below the carrier's natural setpoint with aggressive therapy often causes hypoglycemia without benefit.

Pregnancy is the most important management exception. Serial ultrasound monitoring of fetal abdominal circumference from 26 weeks is recommended, and insulin therapy is only initiated when fetal growth exceeds the 75th percentile. Non-invasive fetal genotyping, where available, can personalise this decision further by identifying which fetuses actually need monitoring for macrosomia.

Interactions

GCK-MODY caused by heterozygous variants behaves as autosomal dominant with full penetrance — nearly all heterozygous carriers have the raised glucose setpoint. The condition does not interact in a meaningful additive way with common type 2 diabetes polygenic risk, because the mechanism is entirely distinct (glucose sensing threshold vs insulin resistance). Homozygous or compound heterozygous GCK variants (two loss-of-function alleles) cause permanent neonatal diabetes mellitus (PNDM), a far more severe neonatal condition requiring insulin from birth — but this is an entirely different clinical entity.